Considerations for therapeutic management of hospitalized adults with cancer and COVID-19
| Hospitalized not requiring supplemental oxygen* | Consider management as nonhospitalized adults with cancer and mild or moderate COVID-19 without hypoxia |
| Insufficient evidence for the use of corticosteroids in the absence of another indication | |
| Hospitalized requiring supplemental oxygen* | Remdesivir |
| Dexamethasone | |
| Second immunomodulator for patients with increasing oxygen needs and systemic inflammation (tocilizumab or baricitinib: tofacitinib if baricitinib is not available and sarilumab if tocilizumab is not available) | |
| Hospitalized requiring mechanical ventilation or extracorporeal membrane oxygenation | Remdesivir is not effective at this stage |
| Dexamethasone | |
| Tocilizumab (sarilumab if tocilizumab is not available) |
| Hospitalized not requiring supplemental oxygen* | Consider management as nonhospitalized adults with cancer and mild or moderate COVID-19 without hypoxia |
| Insufficient evidence for the use of corticosteroids in the absence of another indication | |
| Hospitalized requiring supplemental oxygen* | Remdesivir |
| Dexamethasone | |
| Second immunomodulator for patients with increasing oxygen needs and systemic inflammation (tocilizumab or baricitinib: tofacitinib if baricitinib is not available and sarilumab if tocilizumab is not available) | |
| Hospitalized requiring mechanical ventilation or extracorporeal membrane oxygenation | Remdesivir is not effective at this stage |
| Dexamethasone | |
| Tocilizumab (sarilumab if tocilizumab is not available) |
Some patients might benefit from resting in the prone position89 and need to be educated about breathing exercises to prevent anxiety-provoking severe breathlessness.90